MedMira's Biosensor Division to Receive $3 million from ACOA's Atlantic Innovation Fund
Investment in Maple Biosciences Shall Support Development of Revolutionary Diagnostics
The Atlantic Innovation Fund is a Government of Canada initiative designed to increase leading edge research and development (R&D) carried out in Atlantic Canadian research facilities, which will lead to the launch of new ideas, products, processes and services and contribute directly to the development of new technology-based economic activity. The investment from the Atlantic Innovation Fund will support the development of new diagnostic instruments based on Maple Bioscience's biosensor technology. According to the company, these new diagnostics instruments shall displace the current 30-year old technology and play an important role in the global laboratory diagnostics market sector, currently valued at over USD $22 billion.
Most read news
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.